Mesenchymal Drift May Be a Hidden Driver of Aging and a Target for Rejuvenation
A review proposes that aging cells drift toward a scar-forming mesenchymal state, and that reprogramming or TGF-β blockade may reverse it.
Summary
This perspective review argues that mesenchymal drift (MD), the gradual shift of epithelial and endothelial cells toward a mesenchymal, fibrosis-prone state, is a unifying and tentative hallmark of aging. Transcriptomic data from 42 human tissues show mesenchymal programs rising with age, and high MD levels predicted worse survival in idiopathic pulmonary fibrosis. Preclinical work suggests MD can be reversed: transient Yamanaka-factor reprogramming, safer OSK variants, and TGF-β pathway inhibitors such as RepSox and ALK5 blockers reduced MD signatures and, in mice, improved organ function. An oxytocin plus ALK5 inhibitor combination extended remaining lifespan in frail old male mice. The evidence is mostly preclinical or correlational, and clinical translation remains unproven.
Detailed Summary
Why it matters: Aging is increasingly viewed as a progressive loss of cellular identity. This review proposes that one major form of that loss is mesenchymal drift (MD). In MD, epithelial and endothelial cells slowly adopt mesenchymal traits such as motility, matrix deposition, and weakened cell-cell junctions. The author argues that MD ties together epigenetic erosion, chronic inflammation, and tissue stiffening, and that it may be a tentative hallmark of aging.
What was reviewed: This is a narrative review, not a new experiment. It draws mainly on a pan-tissue transcriptomic analysis (Lu et al., 2025) of 42 human tissues from 948 donors aged 20–79. It also draws on disease cohorts, plasma proteomics, and preclinical reprogramming and pharmacology studies. MD is distinguished from classical EMT/EndoMT. It is low-grade, mosaic, multi-lineage, unfolds over months to years, and appears partially reversible.
Key results: Mesenchymal gene programs rose with age across nearly all tissues, with correlations above 0.3. In a bronchoalveolar lavage cohort of 132 idiopathic pulmonary fibrosis patients, higher MD levels corresponded to much shorter median survival (2,498 days in the low group versus 59 days in the high group). MD signatures also tracked liver disease progression, kidney disease, and heart failure. Plasma proteins such as GDF15 were linked to high-MD states. In reprogramming studies, ZEB1 suppression lowered methylation-based age signatures in fibroblasts. One week of transient OSKM expression suppressed MD before pluripotency markers appeared. OSK and an engineered OCT4 mutant preserved the benefit with less oncogenic risk. In aged mice, cyclic OSKM lowered MD scores in kidney and liver by 25–40%. OSK restored vision in about half of glaucomatous mice, and transient induction reduced wound scarring.
Pharmacological angle: TGF-β receptor inhibitors such as RepSox, which also substitutes for SOX2 in chemical reprogramming, and ALK5/ALK2 inhibitors partially mimicked reprogramming in progeroid ERCC1-deficient mice. In 25-month-old frail mice, oxytocin plus an ALK5 inhibitor extended remaining lifespan by about 73% from treatment onset and median lifespan by about 14% in males. Anti-inflammatory agents and ROCK inhibitors are complementary strategies. Collagen cross-link breakers and lysyl oxidase inhibitors have shown mixed or negative clinical results.
Caveats: Most evidence is correlational, transcriptomic, or from animal and cell models. Some key claims come from one group's work. Reprogramming carries dedifferentiation and tumor risks, and TGF-β inhibition may impair wound healing and immunity. MD is not yet a validated hallmark or clinical biomarker, and no human interventional data show that suppressing it extends healthspan.
Key Findings
- Across 42 human tissues (948 donors), mesenchymal gene programs rose with age, with correlations above 0.3 in nearly all tissues.
- In 132 IPF patients, median survival fell from 2,498 days (low MD) to 59 days (high MD).
- Transient 1-week OSKM expression suppressed MD before pluripotency activation, and OSK or mutant OCT4 variants kept the effect with less tumor risk.
- Cyclic OSKM in aged mice lowered kidney and liver MD scores by 25–40% without teratomas.
- Oxytocin plus an ALK5 inhibitor extended remaining lifespan about 73% in frail 25-month-old mice, with a median lifespan gain of about 14% in males.
Methodology
This is a narrative perspective review that synthesizes published human transcriptomic and proteomic datasets, disease cohorts, and preclinical reprogramming and pharmacology studies. It does not report a systematic search or a meta-analysis, and many quantitative claims rely on a single recent preprint-style analysis (Lu et al., 2025).
Study Limitations
Most findings are correlational, transcriptomic, or from mouse and cell models, and the evidence is concentrated in a few research groups. Reprogramming risks (dedifferentiation, tumorigenesis) and TGF-β inhibition risks (impaired wound healing, immune effects) remain unresolved, and lifespan benefits were seen mainly in male mice. MD is not yet established as a hallmark of aging, and the review itself calls it tentative.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: